TEM Tempus AI Total Debt to Capital

Corporate emblem and logo of Tempus AI, Inc. (TEM)

The digital scalability of the Tempus AI, Inc (TEM) AI platform enables the instantaneous monetization of massive datasets. The dynamics of asset leverage confirm this potential, where the value of 3.29 indicates the current leverage ratio. The business relies on insurance payouts, which mitigates macro shocks, while its status as a bold innovator in genomics fuels investor optimism regarding the company's future success.

Tempus Labs (TEM) Aggregate Debt to Capital: for the period 06/15/2024 - 10/28/2026
Brand item of Tempus AI, Inc.

For Tempus AI, Inc (TEM), which is developing an AI platform for precision medicine, the debt-to-equity financial leverage trend reflects the balance between expansion and stability. This metric determines the extent of borrowed funds relative to shareholders' equity. The calculation is based on dividing total liabilities by net assets. A high ratio signals over-leverage risks, while a low ratio indicates a conservative approach. This indicator allows for an assessment of the cost of aggressively scaling the genomic library.

Key competitors

Debt to Equity Qiagen (QGEN)|Debt to Equity Ratio Ionis Pharmaceuticals, Inc.|Total Debt to Capital RGEN|Total Debt to Capital Avidity Corp RNA|Total Debt to Equity Ratio CRISPR Therapeutics AG (CRSP)|Aggregate Debt to Capital genedx.com WGS|RARE (Ultragenyx) - Total Debt to Capital|BEAM: Debt to Capital|SRPT (Sarepta Therapeutics Inc) - Debt to Equity|TWST (Twist Bioscience Corp) - Total Debt to Equity Ratio|Debt to Equity 10x Genomics, Inc. TXG|Aggregate Debt to Equity intelliatx.com (NTLA)|Total Debt to Equity Ratio STOK|Total Debt to Capital BLFS (BioLife Solutions Inc)|Debt to Equity WVE|MAZE - Total Debt to Capital Coefficient|Total Debt to Equity Ratio Sionna Therapeutics Inc (SION)|PRME - All Debt to Shareholders' Equity Ratio|TSHA: Total Debt to Capital|uniQure NV (QURE) - Total Debt to Capital|MGTX: Total Debt to Capital|Total Debt to Capital Coefficient REGENXBIO Corp (RGNX)|Solid Biosciences Inc. (SLDB) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio ocugen.com (OCGN)|Total Debt to Capital PACB|Benitec Biopharma Inc - Total Debt to Capital Coefficient|Design Pharma (DSGN) - Debt to Equity|RCKT - Debt to Equity Ratio|FDMT (4D Molecular Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Lexeo Therapeutics, Inc.|Korro Bio Inc. (KRRO) - Total Debt to Equity Ratio|Aggregate Debt to Capital Editas Medicine Inc|Silence Therapeutics Inc. - Total Debt to Capital|Debt to Capital PRQR (proqr.com)|Codexis - Debt to Equity|Total Debt to Equity Ratio sangamo.com SGMO|Nautilus Biotechnology Inc (NAUT) - Total Debt to Capital|MGX: Debt to Equity Ratio|Debt to Equity Precision BioSciences, Inc.|Generation Bio (GBIO) - Debt to Equity Ratio|BOLD (Boundless Bio, Inc.) - Total Debt to Capital|Total Debt to Capital Exicure Corp (XCUR)|Total Debt to Equity Ratio Imunon, Inc.|Aggregate Debt to Capital phiopharma.com (PHIO)|MBIO: Total Debt to Capital|TransCode Therapeutics Inc. - Debt to Capital|BNGO: Debt to Equity|APDN: Total Debt to Equity Ratio|Debt to Equity bluebird bio (BLUE)|Aggregate Debt to Equity ImmunoPrecise Antibodies Ltd.|OMGA (Omega) - Total Debt to Equity Ratio|Total Debt to Capital OMIC|RGLS (Regulus Therapeutics) - Debt to Equity|Total Debt to Capital Coefficient syros.com SYRS|Total Debt to Equity Ratio Telesis Bio|All Debt to Shareholders' Equity Ratio TRACON Pharmaceuticals Inc. TCON|Unity Bio - Total Debt to Capital